<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03756870</url>
  </required_header>
  <id_info>
    <org_study_id>REVISE-CTO</org_study_id>
    <nct_id>NCT03756870</nct_id>
  </id_info>
  <brief_title>Revascularization Versus Optimal Medical Therapy of Chronic Total Coronary Occlusions on Left Ventricular Ischemia Reduction</brief_title>
  <acronym>REVISE-CTO</acronym>
  <official_title>REvascularization Versus Optimal Medical Therapy on Left Ventricular ISchemia Reduction: Exploring the Associations Between Ischemia, Functional Outcome and Collaterals in the Treatment of Chronic Total Occlusion Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Randomized trials could not yet establish favourable outcomes of CTO PCI on hard&#xD;
      endpoints such as ejection fraction or mortality, when compared to optimal medical therapy.&#xD;
      However, patients after CTO PCI appeared to be more frequently free of angina complaints, but&#xD;
      the aetiology behind this is not fully understood. The investigators hypothesize that PCI of&#xD;
      the CTO in patients preselected with an ischemic threshold (&gt;12.5%) on cardiac imaging leads&#xD;
      to a reduction of the ischemic burden and therefore an increased benefit on functional&#xD;
      outcomes.&#xD;
&#xD;
      Objective: Primary objective is to determine whether PCI of the CTO will yield a higher&#xD;
      reduction of ischemia assessed by exercise myocardial perfusion SPECT-CT from baseline to&#xD;
      6-month follow-up compared to a control group. Secondary objectives are 1) to evaluate the&#xD;
      effect of PCI of the CTO on improvement in functional status, infarct size and left&#xD;
      ventricular function from baseline to follow-up compared to the control group; 2) to study&#xD;
      the association between ischemia reduction and functional outcome and left ventricular&#xD;
      function; 3) to assess the influence of the collateral flow index on the ischemic burden&#xD;
      (reduction), functional status, infarct size and left ventricular (contractile) function&#xD;
      (hibernation).&#xD;
&#xD;
      Study design: open multicentre randomized trial&#xD;
&#xD;
      Study population: 82 patients eligible for CTO PCI&#xD;
&#xD;
      Intervention: CTO PCI&#xD;
&#xD;
      Primary endpoint: ischemic burden assessed with exercise myocardial perfusion SPECT-CT from&#xD;
      baseline to 6 months follow-up.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2029</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1 parallel design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ischemia</measure>
    <time_frame>6 months follow-up</time_frame>
    <description>Ischemic burden assessed with exercise myocardial perfusion SPECT-CT from baseline to 6 months follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in angina status assessed with the Seattle Angina Questionnaire.</measure>
    <time_frame>6 months, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years</time_frame>
    <description>5 Seattle Angina Questionnaire subscales (0-100), higher scores indicating better angina status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed with the Minnesota Living with Heart Failure Questionnaire (MLHFQ)</measure>
    <time_frame>6 months, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years</time_frame>
    <description>MLHFQ scale (0-105), lower scores indicating better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The left ventricular ejection fraction assessed with cardiac magnetic resonance imaging</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Chronic Total Occlusion of Coronary Artery</condition>
  <arm_group>
    <arm_group_label>CTO PCI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive optimal medical therapy, with percutaneous coronary intervention of the chronic total occlusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OMT</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will receive optimal medical therapy, without percutaneous coronary intervention of the chronic total occlusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous coronary intervention (PCI)</intervention_name>
    <description>A percutaneous coronary intervention of the chronic total occlusion with a drug-eluting stent.</description>
    <arm_group_label>CTO PCI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A chronic total occlusion is present and target lesion. A CTO is required to meet the&#xD;
             following characteristics:&#xD;
&#xD;
               -  A 100% luminal narrowing of the coronary artery without antegrade flow, i.e.&#xD;
                  Thrombolysis in Myocardial Infarction flow grade 0 or 1;&#xD;
&#xD;
               -  Older than 3 months, established with previous PCI or with angiographic&#xD;
                  characteristics;&#xD;
&#xD;
               -  Amenable to percutaneous revascularization.&#xD;
&#xD;
          2. Patient has a clinical indication to perform CTO PCI.&#xD;
&#xD;
          3. A SPECT is performed at baseline to assess ischemia and a cardiac magnetic resonance&#xD;
             imaging (CMR) scan to assess viability, as part of routine patient care. Patients are&#xD;
             deemed eligible for the randomized trial when they meet the ischemic threshold in the&#xD;
             CTO territory.&#xD;
&#xD;
             The ischemic threshold is defined as:&#xD;
&#xD;
               -  &gt;12.5% of ischemia;&#xD;
&#xD;
               -  With &lt;50% transmural extent of infarction.&#xD;
&#xD;
          4. Subject agrees to undergo follow-up SPECT-CT at 6 months after initial inclusion&#xD;
&#xD;
          5. Subject is able to verbally confirm understanding and he/she provides written informed&#xD;
             consent prior to any Clinical Investigation related procedure, as approved by the&#xD;
             appropriate Ethics Committee.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is younger than 18 years of age;&#xD;
&#xD;
          -  Persistent or permanent atrial fibrillation;&#xD;
&#xD;
          -  Presence of a non-MRI compatible cardiac device, i.e. pacemaker or implantable&#xD;
             cardioverter defibrillator;&#xD;
&#xD;
          -  Body weight &gt; 250 kg;&#xD;
&#xD;
          -  Unable to exert, i.e. due to physical disability;&#xD;
&#xD;
          -  Any contraindication for SPECT or CMR, i.e. cerebrovascular clips, claustrophobia;&#xD;
&#xD;
          -  Known renal insufficiency (estimated Glomerular Filtration Rate [eGFR] &lt;60&#xD;
             mL/min/1.73m2 or serum creatinine level of &gt;2.5 mg/dL or subject on dialysis);&#xD;
&#xD;
          -  Hypersensitivity or allergy to contrast with inability to properly pre-hydrate;&#xD;
&#xD;
          -  Presence of a comorbid condition with a life expectancy of less than one year;&#xD;
&#xD;
          -  Participation in another trial;&#xD;
&#xD;
          -  Subject is belonging to a vulnerable population (per investigator's judgment, e.g.,&#xD;
             subordinate hospital staff) or is unable to read or write.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Prof. J.P.S. Henriques, MD PhD</last_name>
    <phone>+31205666405</phone>
    <email>j.p.henriques@amc.uva.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ms. A. van Veelen, MD</last_name>
    <phone>+31205666405</phone>
    <email>a.vanveelen@amc.uva.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Amsterdam UMC, location AMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna van Veelen, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 26, 2018</study_first_submitted>
  <study_first_submitted_qc>November 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2018</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>J.P.S Henriques</investigator_full_name>
    <investigator_title>Principal Investigator, Head of Catheterization Laboratory</investigator_title>
  </responsible_party>
  <keyword>Chronic total coronary occlusion</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>Optimal medical therapy</keyword>
  <keyword>Myocardial ischemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Occlusion</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

